Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

Aleksandra M. Wojtas; Yari Carlomagno; Jonathon P. Sens; Silvia S. Kang; Tanner D. Jensen; Aishe Kurti; Kelsey E. Baker; Taylor J. Berry; Virginia R. Phillips; Monica Casey Castanedes; Ayesha Awan; Michael DeTure; Cristhoper H.Fernandez De Castro; Ariston L. Librero; Mei Yue; Lillian Daughrity; Karen R. Jansen-West; Casey N. Cook; Dennis W. Dickson; Leonard Petrucelli; John D. Fryer

doi:10.1186/s40478-020-01079-1

Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

Aleksandra M. Wojtas, Yari Carlomagno, Jonathon P. Sens, Silvia S. Kang, Tanner D. Jensen, Aishe Kurti, Kelsey E. Baker, Taylor J. Berry, Virginia R. Phillips, Monica Casey Castanedes, Ayesha Awan, Michael DeTure, Cristhoper H.Fernandez De Castro, Ariston L. Librero, Mei Yue, Lillian Daughrity, Karen R. Jansen-West, Casey N. Cook, Dennis W. Dickson, Leonard PetrucelliJohn D. Fryer

Neuroscience

Research output: Contribution to journal › Article › peer-review

Abstract

The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD.

Original language	English (US)
Article number	210
Journal	Acta Neuropathologica Communications
Volume	8
Issue number	1
DOIs	https://doi.org/10.1186/s40478-020-01079-1
State	Published - Dec 2020

Keywords

Alzheimer’s disease
Clusterin
Tau
Tauopathy

ASJC Scopus subject areas

Pathology and Forensic Medicine
Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1186/s40478-020-01079-1

Cite this

Wojtas, A. M., Carlomagno, Y., Sens, J. P., Kang, S. S., Jensen, T. D., Kurti, A., Baker, K. E., Berry, T. J., Phillips, V. R., Castanedes, M. C., Awan, A., DeTure, M., De Castro, C. H. F., Librero, A. L., Yue, M., Daughrity, L., Jansen-West, K. R., Cook, C. N., Dickson, D. W., ... Fryer, J. D. (2020). Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation. Acta Neuropathologica Communications, 8(1), [210]. https://doi.org/10.1186/s40478-020-01079-1

Wojtas, AM, Carlomagno, Y, Sens, JP, Kang, SS, Jensen, TD, Kurti, A, Baker, KE, Berry, TJ, Phillips, VR, Castanedes, MC, Awan, A, DeTure, M, De Castro, CHF, Librero, AL, Yue, M, Daughrity, L, Jansen-West, KR, Cook, CN , Dickson, DW , Petrucelli, L & Fryer, JD 2020, 'Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation', Acta Neuropathologica Communications, vol. 8, no. 1, 210. https://doi.org/10.1186/s40478-020-01079-1

@article{b58028cb140844518703c1dbaa2eaf08,

title = "Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation",

abstract = "The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer{\textquoteright}s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD.",

keywords = "Alzheimer{\textquoteright}s disease, Clusterin, Tau, Tauopathy",

author = "Wojtas, {Aleksandra M.} and Yari Carlomagno and Sens, {Jonathon P.} and Kang, {Silvia S.} and Jensen, {Tanner D.} and Aishe Kurti and Baker, {Kelsey E.} and Berry, {Taylor J.} and Phillips, {Virginia R.} and Castanedes, {Monica Casey} and Ayesha Awan and Michael DeTure and {De Castro}, {Cristhoper H.Fernandez} and Librero, {Ariston L.} and Mei Yue and Lillian Daughrity and Jansen-West, {Karen R.} and Cook, {Casey N.} and Dickson, {Dennis W.} and Leonard Petrucelli and Fryer, {John D.}",

note = "Funding Information: J.D.F. was supported by the Mayo Foundation, the Mayo Clinic Center for Individualized Medicine, a Mayo Clinic Gerstner Family Career Development Award, the Ed and Ethel Moore Alzheimer{\textquoteright}s Disease Research Program of Florida Department of Health (6AZ06), the Gilmer Family Foundation, Alzheimer{\textquoteright}s Association NIRP-12-25928, The Rotary Coins for Alzheimer{\textquoteright}s Research Trust Fund, CureAlz Foundation, Ben-Dov Family Foundation, and NIH Grants NS084974, AG062556, AG062110, NS094137, AG057997, AG062077, NS110435, AG047327, and AG049992. Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

doi = "10.1186/s40478-020-01079-1",

language = "English (US)",

volume = "8",

journal = "Acta neuropathologica communications",

issn = "2051-5960",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

AU - Wojtas, Aleksandra M.

AU - Carlomagno, Yari

AU - Sens, Jonathon P.

AU - Kang, Silvia S.

AU - Jensen, Tanner D.

AU - Kurti, Aishe

AU - Baker, Kelsey E.

AU - Berry, Taylor J.

AU - Phillips, Virginia R.

AU - Castanedes, Monica Casey

AU - Awan, Ayesha

AU - DeTure, Michael

AU - De Castro, Cristhoper H.Fernandez

AU - Librero, Ariston L.

AU - Yue, Mei

AU - Daughrity, Lillian

AU - Jansen-West, Karen R.

AU - Cook, Casey N.

AU - Dickson, Dennis W.

AU - Petrucelli, Leonard

AU - Fryer, John D.

N1 - Funding Information: J.D.F. was supported by the Mayo Foundation, the Mayo Clinic Center for Individualized Medicine, a Mayo Clinic Gerstner Family Career Development Award, the Ed and Ethel Moore Alzheimer’s Disease Research Program of Florida Department of Health (6AZ06), the Gilmer Family Foundation, Alzheimer’s Association NIRP-12-25928, The Rotary Coins for Alzheimer’s Research Trust Fund, CureAlz Foundation, Ben-Dov Family Foundation, and NIH Grants NS084974, AG062556, AG062110, NS094137, AG057997, AG062077, NS110435, AG047327, and AG049992. Publisher Copyright: © 2020, The Author(s).

PY - 2020/12

Y1 - 2020/12

N2 - The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD.

AB - The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD.

KW - Alzheimer’s disease

KW - Clusterin

KW - Tau

KW - Tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85096951253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096951253&partnerID=8YFLogxK

U2 - 10.1186/s40478-020-01079-1

DO - 10.1186/s40478-020-01079-1

M3 - Article

C2 - 33261653

AN - SCOPUS:85096951253

VL - 8

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

IS - 1

M1 - 210

ER -

Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this